Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0VBVDR
ADC Name
ADCT-502
Synonyms
ADCT 502; ADCT502
   Click to Show/Hide
Organization
ADC Therapeutics SA
Drug Status
Terminated in phase 1
Indication
In total 5 Indication(s)
Bladder cancer [ICD11:2C94]
Terminated in phase 1
Breast cancer [ICD11:2C60-2C65]
Terminated in phase 1
Esophageal cancer [ICD11:2B70]
Terminated in phase 1
Gastric cancer [ICD11:2B72]
Terminated in phase 1
Non-small cell lung cancer [ICD11:2C25]
Terminated in phase 1
Drug-to-Antibody Ratio
1.7
Structure
Antibody Name
Trastuzumab
  Antibody Info 
Antigen Name
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
  Antigen Info 
Payload Name
SG3199
  Payload Info 
Therapeutic Target
Human Deoxyribonucleic acid (hDNA)
  Target Info 
Linker Name
Mal-PEG8-Val-Ala-PABC
  Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
Combination Type
Tesirine
Puchem SID
404720412
TTD ID
D05CRY
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Objective Response Rate (ORR)  NCT03125200
Phase 1
A phase 1, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ADCT-502 in patients with advanced solid tumors with HER2 expression.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Objective Response Rate (ORR)
20.00% (150 ug/kg)
Patients Enrolled
Patients with HER2-positive advanced solid tumors.
Administration Dosage
Seven dose cohorts (30, 60, 120, 150, 180, 210, 240 ug/kg on day 1, iv once every 3 weeks.
Related Clinical Trial
NCT Number NCT03125200  Clinical Status Phase 1
Clinical Description A phase 1, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ADCT-502 in patients with advanced solid tumors with HER2 expression.
References
Ref 1 A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.